DaVita HealthCare (DVA) Upgraded to Strong Buy: Here's Why
DaVita HealthCare (DVA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
DaVita HealthCare (DVA) Exceeds Market Returns: Some Facts to Consider
DaVita HealthCare (DVA) closed at $169.90 in the latest trading session, marking a +0.86% move from the prior day.
Is DaVita (DVA) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Industry Outlook Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare
Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare have been highlighted in this Industry Outlook article.
DaVita HealthCare (DVA) Ascends But Remains Behind Market: Some Facts to Note
The latest trading day saw DaVita HealthCare (DVA) settling at $162.36, representing a +0.22% change from its previous close.
DaVita HealthCare (DVA) Rises As Market Takes a Dip: Key Facts
DaVita HealthCare (DVA) closed the most recent trading day at $152.69, moving +0.77% from the previous trading session.
DaVita HealthCare (DVA) Stock Dips While Market Gains: Key Facts
The latest trading day saw DaVita HealthCare (DVA) settling at $151.53, representing a -0.84% change from its previous close.
Should Value Investors Buy DaVita (DVA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $155.06, denoting a +1.33% change from the preceding trading day.
DaVita Stock Gains 40.1% Year to Date: What's Behind the Rally?
Strength in kidney care services and expansion into international markets raise optimism for DVA stock.
DaVita: Better Results Than Fresenius, But A 'Hold' Due To Valuation
Despite operational success and growth potential, I rate DaVita Inc. a “Hold” due to its high debt, lack of dividend, and current overvaluation. DaVita excels in dialysis services but faces significant risks from debt servicing costs, macroeconomic factors, and potential policy changes. The company's recent financial performance, including a decline in net income and increased debt costs, underscores my conservative valuation approach.
